In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
GHTC member Aeras has announced that it has signed an agreement with GlaxoSmithKline Vaccines (GSK) to jointly advance the development of a tuberculosis (TB) vaccine candidate.
A new series in the Financial Times looks at neglected tropical diseases, including their economic burden, the need for improved treatment methods, and the need for research and development funding.
Genocea Biosciences, a company that advances vaccines for infectious diseases, has raised $30 million in new funding from groups like the Bill & Melinda Gates Foundation.
An article examines how the priority review voucher program, an “innovative funding model for research into neglected diseases,” has “finally come of age.”
GSK also announced this week that it plans to make clinical trial data available to other researchers, as well as open its TB compound library to help stimulate research.